Evidence map›Paper›PMID 40950970›Full record

ArticleFrontiers in medicine2025

Association of leukocyte telomere length and HbA1c with post-COVID-19 syndrome in type 2 diabetes: a cross-sectional pilot study.

Anton Matviichuk, Dmytro Krasnienkov, Viktoriia Yerokhovych, Yeva Ilkiv, Veronika Korcheva, Oleksandr Gurbych, Anna Shcherbakova, Pavlina Botsun, Tetyana Falalyeyeva, Oksana Sulaieva and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anton Matviichuk *Endocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine.
Dmytro Krasnienkov *Laboratory of Epigenetics, Institute of Gerontology Academy of Medical Sciences of Ukraine, Kyiv, Ukraine.
Viktoriia YerokhovychEndocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine.
Yeva IlkivEndocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine.
Veronika KorchevaLaboratory of Epigenetics, Institute of Gerontology Academy of Medical Sciences of Ukraine, Kyiv, Ukraine.
Oleksandr GurbychBlackthorn AI, Ltd., London, United Kingdom.
Anna ShcherbakovaMedical Laboratory CSD, Kyiv, Ukraine.
Pavlina BotsunMedical Laboratory CSD, Kyiv, Ukraine.
Tetyana FalalyeyevaTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Oksana Sulaieva *Medical Laboratory CSD, Kyiv, Ukraine.
Nazarii Kobyliak *Endocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Leukocyte telomere length is considered a promising prognostic marker associated with COVID-19 severity, adverse outcomes (hospital admission, need for critical care, and respiratory support), and mortality. However, the contribution of telomere length to post-COVID-19 syndrome (PCS) development is unclear. Aim: This study aimed to evaluate the association between telomere shortening and the course of PCS in patients with type 2 diabetes (T2D) and to determine whether telomere length is linked to clinical phenotype, gender, and biological age. Materials and methods: In this cross-sectional study, 66 T2D patients who had recovered from COVID-19 were enrolled. Patients were divided into two groups depending on PCS development: the PCS group ( Results: We observed a significantly lower mean of telomere length in T2D patients with PCS as compared to those without it (1.09 ± 0.19 and 1.28 ± 0.24; Conclusion: Shorter telomere length and higher HbA1c levels were significantly associated with the presence of PCS in our cohort of individuals with T2D. These factors may represent potential biomarkers that warrant further investigation.

Indexed as

agingbiomarkersHbA1clong COVID-19machine learningpost-COVID-19telomere lengthtype 2 diabetes

Identifiers

PMID40950970
PMCPMC12425890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.